Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
116Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $673.00M | $-575.00M | $-5.83 |
| 2024 | $560.23M | $-569.18M | $-6.29 |
| 2023 | $434.25M | $-606.64M | $-8.25 |
| 2022 | $363.33M | $-707.42M | $-10.12 |
| 2021 | $351.41M | $-454.02M | $-6.70 |
Social Signal Score
Earnings
Tue, Nov 3(in 3 months)
Consensus estimate $-0.65 per share
Typical surprise -5.3% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$-0.90 vs $-1.22beat
- Tue, May 5$-1.84 vs $-1.49miss
- Thu, Feb 12$-1.29 vs $-1.20miss
- Tue, Nov 4$-1.81 vs $-1.23miss
- Tue, Aug 5$-1.17 vs $-1.27beat
- Tue, May 6$-1.57 vs $-1.54miss
Estimates and results for RARE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
RAREhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsseekingalpha.com·1d ago·Positive
Ultragenyx: Undervalued Ahead Of Two FDA Decisions Ultragenyx Pharmaceutical is rated a soft Buy at $26.75, with a probability-weighted fair value of ~$32 per share. Two near-term FDA decisions: DTX401 on Aug 23 and another for UX111 on Sept 19. DTX401 has a cleaner regulatory case, but UX111 has a credible approval path. Using 80% approval odds for DTX401 and 65% for UX111, our probability-weighted value is approximately $32 per share versus a current share price near $27.
View source ↗